FIT Overview. Objectives 6/23/2014

Similar documents
Be it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE

COLORECTAL CANCER SCREENING &THE FECAL IMMUNOCHEMICAL TEST (FIT) MATHEW ESTEY, PHD, FCACB CLINICAL CHEMIST

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients

An Updated Approach to Colon Cancer Screening and Prevention

Updates in Colorectal Cancer Screening & Prevention

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?

FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test

Colon Cancer Screening Past, Present & Future

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne

Microbiome as a marker for CRC screening

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

Colorectal Cancer Screening

Page 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!

MITIGATING.POTENTIAL.BIAS

Primary care at the forefront of colorectal cancer screening

Championing Information Management to Improve System Performance and Patient Care

Colorectal Cancer Screening and Surveillance

(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Rx Only. Detecting Cancer In Blood.

Colorectal cancer screening

THE NEW ZEALAND MEDICAL JOURNAL

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

IEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries

Colon Cancer Screening. A Provider Opinion Survey

IARC Handbook Volume 17: Colorectal Cancer Screening. Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17

CRC Risk Factors. U.S. Adherence Rates Cancer Screening. Genetic Model of Colorectal Cancer. Epidemiology and Clinical Consequences of CRC

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist

Dr Alasdair Patrick Gastroenterologist

Guidance on Implementing FIT-based Screening Programs. June 29th, :00pm ET

Financial Disclosers

HTA September health technology assessment rapid review. Supporting Informed Decisions. Canadian Agency for Drugs and Technologies in Health

FREQUENTLY ASKED QUESTIONS

Challenges for Colorectal Cancer Screening

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

TPMG experience in improving colorectal cancer screening rates

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests

Colorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers

Colorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital

Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem

Transition to Fecal Immunochemical Testing (FIT)

Colorectal Cancer Prevention Hospital Universitário São Paulo University

National Data Analysis

Sarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction

Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005

WEO CRC SC Meeting. Vienna, Austria October 14, 2016

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.

The Dutch bowel cancer screening program Relevant lessions for Ontario

Irritable Bowel Syndrome vs Inflammatory Bowel Disease

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative

th Medical Group Report Card

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee

Cancer screening information in one complete report in Alberta Netcare

Alberta Colorectal Cancer Screening Program

Colorectal Cancer Screening: The Science Behind the Guidelines. CRC Incidence North Dakota. Colorectal Cancer (CRC) CRC Incidence North Dakota

An Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018

Blood Based Screening

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening

Risk scoring incorporating FIT in triage of symptomatic patients

Positive Results on Fecal Blood Tests

Selected Controversies. Cancer Screening. Breast Cancer Screening. Selected Controversies. Page 1. Using Best Evidence to Guide Practice

Faecal testing in colorectal cancer screening: State of the Art. Prof Stephen P. Halloran

The choice of methods for Colorectal Cancer Screening; The Dutch experience

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy

FEP Medical Policy Manual

Information Pack for GP s The implementation of the Faecal Immunochemical Test (FIT) across the South West

Recommendations on Screening for Colorectal Cancer 2016

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool

Improving Access to Endoscopy at Safety-Net Hospitals. Lukejohn W. Day MD Assistant Professor of Medicine

Bowel Cancer Screening

Colorectal Cancer Screening. Paul Berg MD

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

Colorectal Cancer Screening: A Clinical Update

Page 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.

Colorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi

COLON CANCER SCREENING: AN UPDATE

GREENWOOD PUBLIC SCHOOL DISTRICT PHYSICAL EDUCATION

NATIONAL SCREENING COMMITTEE

Bowel cancer screening and prevention

Implementation of Faecal Immunochemical Testing as the screening test for Bowel Screening. Programme in Wales

HOW TO EVALUATE ACTIVITIES INTENDED TO INCREASE AWARENESS AND USE OF COLORECTAL CANCER SCREENING. Using your toolkit to conduct an evaluation

COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.

Learning and Earning with Gateway Professional Education CME/CEU Webinar Series

Implementing of Population-based FOBT Screening

National Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT

Cancer Screening I have no conflicts of interest. Principles of screening. Cancer in the World Page 1. Letting Evidence Be Our Guide

Setting The setting was primary and secondary care. The economic study was carried out in Taiwan.

Thank You to Our Sponsors: Evaluations & CE Credits. Featured Speakers. Conflict of Interest & Disclosure Statements

What I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2

Colorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist

Dr Alasdair Patrick. Dr Nagham Al-Mozany. 9:45-10:10 Where Are We Up To With Bowel Cancer Screening?

Practical challenges in establishing and running the Czech national colorectal cancer screening programme

Transcription:

ADDS 2014: Plenary 2 FIT Update Clarence Wong, MD FRCPC Associate Professor of Medicine, University of Alberta Provincial Medical Lead, Alberta Colorectal Cancer Screening Program 1 Objectives After this session, the attendee will have increased knowledge regarding fecal immunochemical testing (FIT) in regards to: Evidence for CRC and AA detection Test characteristics and effectiveness FIT results in Alberta since implementation 2 FIT Overview 3 1

Why FIT? Long GI referral wait times Improved sensitivity over FOBT Population strategy?trust by family physicians/patients 4 ACRCSP FIT Launch Nov 18, 2013 5 Fecal immunochemical test (FIT) Immunochemical based test for globin in the stool FIT for Alberta: Polymedco OC FIT-CHEK 6 2

FIT Advantages No dietary change FIT only detects human globin No peroxidase reaction More specific for lower GI bleeding Single collection from one sample annually Easier to use Better completion rate in studies Quantifiable 7 FIT Indications in Alberta Average Risk 50 74 Moderate Risk 40 49 (FDR >60) 75 84 carefully weight quality of life, commodities and life expectancy. Individualize screening and work with local endoscopists 8 When NOT to use FIT Symptomatic patients Acute care settings Interval FIT Out of age range patients If quality of life is poor or life expectancy is less than 10 yrs 9 3

FIT Evidence 10 FIT Accuracy 11 Lee et al., AIM 2014 1383 records screened 19 studies/data sets included in meta analysis 12 4

Bottom Line Lee et al., AIM 2014 Pooled Sensitivity 0.79 Pooled Specificity 0.94 Accuracy 95% Overall, a moderately sensitive and highly specific test for CRC 13 FIT Cutoffs & Findings 14 Van Rossum, BJC 2009 15 5

Bottom Line van Rossum BJC 2009 In Average Risk group 50 74, at a cutoff of 75 ng/ml: FIT + 1 in 13 CRC FIT + 1 in 2 AA or CRC 16 FIT vs Colonoscopy Strategy 17 57,404 subjects randomly assigned to COL or FIT Quintero et al., NEJM 2012 18 6

Quintero et al Colonoscopy 26,703 NNScope for 1 Cancer 191 18 FIT 26,599 Complications (%) 0.5 0.1 Overall Screened 5059 10,611 Rate of participation (%) 24.6 34.2 19 Bottom Line Quintero NEJM 2012 Using a FIT population strategy: Increased overall participation Detected the same number of CRC Reduced the number of colonoscopies need to detect 1 CRC 20 Factors Influencing Fecal Immunochemical Test Positivity Rate: Demographic, Pathological, Behavioral and Environmental Effects Erin L. Symond, Graeme P. Young et al. The Comparative Cost Effectiveness of Faecal Immunochemical Tests vs. Screening Colonoscopy in the Detection of Neoplastic Lesions Martin C. Wong, Joseph J. Y. Sung et al. 21 7

Effect of temperature on FIT Max temperature OR 95% CI 17 25 o C 0.95 0.83 1.10 26 34 o C 0.81 0.68 0.95 >34 o C 0.69 0.53 0.91 Cost Effectiveness of FIT Annual FIT (5,863) Colonoscopy (4,869) Projection 1,004,618 Projection834,298 Findings N Cost per finding (US$) N Cost per finding (US$) Adenoma 15,935 16,085 197,466 4,719 Adv Neoplasia 9,596 26,712 32,227 28,913 CRC 1,713 149,590 2,400 388,268 22 Impact on Colorectal Cancer Mortality of Screening Programmes Based on Immunochemical Fecal Occult Blood Test in the Veneto Region (Italy) Zorzi et al Aim: Impact of FIT screening on CRC mortality Methods Comparison of Early Screening Area (ESA) 2002 2004 vs Late Screening Area (LSA) 2008 2009 Analysis of CRC mortality in 50 74 23 Zorzi et al CRC Reduction of 25% Mainly female 24 8

FIT in Alberta 25 How many FITs completed? (November 18, 2013 April 30, 2014) 60000 50000 50582 125, 247 40000 30000 20000 10000 0 35718 16168 9207 12373 1199 South Calgary Central Edmonton North Missing 26 Number of FITs completed in Alberta by Age (November 18, 2013 April 30, 2014) 120000 100000 80000 98814 125, 247 60000 40000 20000 0 9718 12476 12373 1871 <40 40 49 50 74 75 84 >85 27 9

FIT positivity by age 28 July Sept 2013 FOBT report 3.3% Positive Rate 29 FIT referrals SCOPE Edmonton 900 800 700 600 500 400 300 200 100 0 Total referrals FIT + 30 10

FIT referrals CCSC 450 400 350 300 250 200 150 100 50 0 FOBT 7 FIT FOBT & FIT + Oct 13 Nov 13 Dec 13 Jan 14 Feb 14 Mar 14 Apr 14 31 Number of FITs Completed in Alberta by Zone (November 18, 2013 April 30, 2014) Missing 1199 1% South North 9207 12373 7% 10% Calgary 35718 29% Edmonton 50582 40% Central 16168 13% 32 CCSC Findings (N) to May 23/14 N 21 102 69 264 376 974 Cancer AA SSA NonAA Normal Total FIT 0 200 400 600 800 1000 33 Courtesy Dr. S. Heitman, CCSC 11

CCSC Findings (%) to May 23/14 % 2.2 10.5 7.1 27.1 38.6 78.3 Cancer AA SSA NonAA Normal Scrn Related 0 20 40 60 80 34 Courtesy Dr. S. Heitman, CCSC Modifying the FIT cutoff? 35 Summary FIT is an immunochemical test with moderate sensitivity and high specificity for CRC It has higher acceptance among patients FIT detects advanced adenomas FIT reduces the number needed to scope to find CRC In Alberta, FIT has been implemented since November 2013 Initial results show high acceptance Positive rate ~10% High number of significant findings 36 12